Open AccessSurveillance of anti-tuberculosis drug resistance in Europe, 1999
Author(s) -
A Infuso,
D Antoine,
Philippe Barboza,
Dennis Falzon
Publication year - 2002
Publication title -
euro surveillance/eurosurveillance
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.766
H-Index - 104
eISSN - 1560-7917
pISSN - 1025-496X
DOI - 10.2807/esm.07.06.00423-en
Subject(s) - tuberculosis , incidence (geometry) , medicine , rifampicin , drug resistance , demography , isoniazid , soviet union , environmental health , geography , biology , political science , pathology , physics , microbiology and biotechnology , sociology , politics , law , optics
With the exception of Israel, representative data from Western and Central Europe indicate consistently low levels of resistance to isoniazid (0-9,3%) or rifampicin (0-2,1%) and of multidrug resistance (0-2,1%) among new tuberculosis (TB) cases. Resistance is more frequent among previously treated cases, but comparisons of data should be done cautiously, as criteria for inclusion in TB notifications may vary across countries. In Western Europe, drug resistance is more frequent among cases of foreign origin, a group with high TB incidence. In 1999, cases of foreign origin accounted for over 90% of the MDR cases in the West, and for all MDR cases notified in Israel. The majority of foreign born cases notified originated from Africa or Asia. In the East, representative data from the Baltic States show that overall, 15% of TB cases notified in 1999 were MDR, among the highest proportion worldwide and indicating inadequacies in previous treatment programmes. In the other countries of the former Soviet Union, non-representative data show high levels of resistance which, along with data from the Baltic states and results of surveys, are very alarming.